On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use Authorization of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-ﾵg dose in the three-dose primary series for children 6 months through 4 years of age.

Children in this age group can receive a primary series consisting of two 3-ﾵg doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-ﾵg dose of the bivalent vaccine to complete the primary series.